NovoCure Reports Executive Changes & Compensation on Jan 4

TL;DR

**NovoCure just announced executive changes and compensation details, watch for strategic shifts.**

AI Summary

NovoCure Ltd. filed an 8-K on January 4, 2024, to report the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers. This filing also includes Regulation FD Disclosure and Financial Statements and Exhibits. This matters to investors because changes in leadership and executive compensation can signal shifts in company strategy, financial health, or future performance, potentially impacting the stock's valuation.

Why It Matters

Changes in executive leadership and compensation can significantly influence a company's strategic direction and operational efficiency, directly affecting investor confidence and stock performance.

Risk Assessment

Risk Level: medium — Changes in leadership can introduce uncertainty regarding future company direction and stability, warranting a medium risk assessment.

Analyst Insight

Investors should monitor subsequent filings or company announcements for specific details regarding the executive changes and compensation, as these will provide clearer insights into potential strategic shifts and their impact on the company's future.

Key Players & Entities

• NovoCure Ltd. (company) — registrant filing the 8-K
• January 4, 2024 (date) — date of earliest event reported and filing date
• 001-37565 (other) — Commission File Number
• NVCR (other) — Trading Symbol for Ordinary Shares
• The Nasdaq Stock Market LLC (other) — exchange where Ordinary Shares are registered

FAQ

Key Financial Figures

• $525,000 — d will receive an annual base salary of $525,000 per year. In addition, Mr. Leonard is e
• $500,000 — h will receive an annual base salary of $500,000 per year through June 30, 2024 and $120
• $120,000 — ,000 per year through June 30, 2024 and $120,000 per year from July 1, 2024 through the

Filing Documents

• nvcr-20240104.htm (8-K) — 37KB
• ex101leonardemploymentagre.htm (EX-10.1) — 118KB
• ex102shahemploymentagreeme.htm (EX-10.2) — 112KB
• managementupdatejanuary420.htm (EX-99.1) — 10KB
• 0001645113-24-000002.txt ( ) — 458KB
• nvcr-20240104.xsd (EX-101.SCH) — 2KB
• nvcr-20240104_lab.xml (EX-101.LAB) — 23KB
• nvcr-20240104_pre.xml (EX-101.PRE) — 12KB
• nvcr-20240104_htm.xml (XML) — 3KB

02(e) Compensatory Arrangements of Certain Officers

Item 5.02(e) Compensatory Arrangements of Certain Officers Frank Leonard Employment Agreement Effective January 1, 2024, the Company appointed Frank Leonard, Executive Vice President and President, Novocure Oncology. In connection with his appointment, Mr. Leonard has entered into a new employment agreement with a subsidiary of the Company dated January 4, 2024 (the "Leonard Employment Agreement"), and effective January 1, 2024 replaces his existing employment agreement, dated as of May 3, 2023. Under the Leonard Employment Agreement, Mr. Leonard will receive an annual base salary of $525,000 per year. In addition, Mr. Leonard is eligible to receive a discretionary annual cash bonus having a target of 60% of his annual base salary based on achievement of performance goals set by Chief Executive Officer or the Board (or committee thereof) in their sole discretion, and further subject to his continued employment through the payment date. Mr. Leonard is generally eligible to participate in Company's 2015 Omnibus Incentive Plan as determined by the Board (or committee thereof). Further, Mr. Leonard is eligible to participate in the employee benefits generally provided to similarly-situated executive employees, subject to the satisfaction of any eligibility requirements. Upon termination of Mr. Leonard's employment by the Company without cause (but for reasons other than death or disability) or resignation by Mr. Leonard for good reason (each as defined in the Leonard Employment Agreement, a "Qualifying Termination") prior to a change in control, subject to Mr. Leonard's execution without revocation of a release of claims, he will be eligible to receive 75% of his annual base salary, payable in substantially equal installments in accordance with the Company's payroll practices over a period of nine (9) months from the date of the Qualifying Termination. Upon a Qualifying Termination within 12 months following a change in control, and subject to Mr. Leonard's exe

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On January 4, 2024, NovoCure Limited (the "Company" or "Novocure"), issu ed a press release announcing the appointment of Dr. Nicholas Leupin, 50, as the Company's Chief Medical Officer. Dr. Leupin will oversee medical affairs, medical safety, and clinical development operations. A copy of the press release is attached hereto as Exhibit 99.1. The information contained in item 7.01 of this Current Report shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Leonard Employment Agreement # 10.2 Shah Employment Agreement # 99.1 Press Release of NovoCure Limited, dated January 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) # Compensation plans and arrangements for executive officers and others.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: January 4, 2023 By: /s/ Ashley Cordova Name: Ashley Cordova Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR